Eupraxia Pharmaceuticals Inc has seen notable fluctuations in its stock price this week, reflecting ongoing developments in its clinical initiatives.
Eupraxia Pharmaceuticals Inc (TSX: EPRX) experienced a decline of 4.75% in its stock price on Tuesday, closing at C$8.83. Over the past week, the stock has decreased by 2.86%, contributing to a year-to-date decline of 15.58%. These movements come amidst limited news coverage, as the company continues to navigate its clinical trials and financial strategies.
Investor takeaway: Investors should consider the implications of Eupraxia's clinical progress and financial health as the company works to advance its lead program, EP-104GI. The stock's recent performance reflects broader market sentiment and investor confidence in its future potential.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$617.99M
52W high
$12.86
52W low
$6.94
1W change
+2.53%
Beta
1.50
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 71.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+71.5% Upside
Current Price
C$9.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
57.5%
Annualized
90-Day Vol
57.6%
Annualized
Trend (90d)
-34.1%
Annualized drift
90d Mean
C$8.26
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.96 | C$7.35 – C$10.93 |
| 60 trading days | C$8.60 | C$6.50 – C$11.39 |
| 90 trading days | C$8.26 | C$5.86 – C$11.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$8.83
Eupraxia Pharmaceuticals Inc's stock closed at C$8.83, down 4.75% on Tuesday.
Bull case
Eupraxia's recent financial results show promising responses in its clinical trials, especially with EP-104GI, which could lead to future growth if successful. The company has also strengthened its financial position through recent public offerings.
Bear case
Despite the positive outlook from analysts, Eupraxia's negative return on equity (-54.5%) and ongoing losses may concern investors. The stock's performance has been volatile, and its dependence on clinical trial outcomes adds significant risk.
Price Action Overview
Advertisement
Eupraxia Pharmaceuticals Inc's stock closed at C$8.83 on Tuesday, reflecting a 4.75% decrease for the day. Over the past week, the stock has seen a decline of 2.86%, while the month-to-date performance shows a slight decrease of 2.54%. Year-to-date, the stock has dropped by 15.58%, indicating a challenging market environment for the company.
Company News and Developments
Currently, there are no major news announcements impacting Eupraxia Pharmaceuticals Inc. However, recent headlines highlight the company's financial results and public offerings. Notably, Eupraxia reported strong responses in the highest dose cohort of its lead program, EP-104GI, in its Q1 2026 financial results. The successful completion of a US$63.2 million public offering aims to support ongoing clinical trials, which may positively influence investor sentiment in the long term.
Technical Picture
From a technical standpoint, Eupraxia's stock is currently trading below its 50-day moving average of C$9.33 and its 200-day moving average of C$9.71, indicating a bearish trend. The stock's 52-week range is between C$6.72 and C$12.86, with the current price at approximately 34% of this range. With a beta of 1.50, the stock exhibits higher volatility compared to the broader market. The recent trading volume of 32,238 shares is significantly lower than the 20-day average of 82,236 shares, suggesting reduced investor interest.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
